drugset
drugset / Trial / NCT00005845

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

NCT00005845 ↗

Phase 1 Completed 65 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of tipifarnib in treating patients with myelodysplastic syndromes. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2002-06
Primary completion
2009-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject tipifarnib Small molecule — Oral

Indications

chronic myelomonocytic leukemia myelodysplastic syndrome with excess blasts myelodysplastic syndrome with multilineage dysplasia myelodysplastic syndrome with ring sideroblasts refractory anemia with excess blasts in transformation